Cell Therapy Company Achieves Commercial Manufacturing

Cell Therapy Company Achieves Commercial Manufacturing

Overview

An innovative cell therapy company transitioned from Phase 3 clinical supply to commercial manufacturing for an autologous CAR-T therapy.

Challenges Faced

• Complex, patient-specific manufacturing
• Strict chain of custody requirements
• Vein-to-vein timing constraints

Solution Architecture

Manufacturing Network Design

• Hub-and-spoke model with regional facilities
• Centralized quality oversight
• Distributed manufacturing for patient access

Technology Implementation

• Closed, automated manufacturing system
• Real-time batch tracking
• Electronic batch records

Outcomes

• 98% manufacturing success rate
• 14-day average vein-to-vein time
• Successful regulatory approvals in US, EU, Japan

Lessons Learned

1. Early investment in automation pays dividends
2. Regional manufacturing improves patient access
3. Integrated IT systems enable tracking